Biomimetic Cell-Derived Nanoparticles: Emerging Platforms for Cancer Immunotherapy.

Abstract

Cancer immunotherapy can significantly prevent tumor growth and metastasis by activating the autoimmune system without destroying normal cells. Although cancer immunotherapy has made some achievements in clinical cancer treatment, it is still restricted by systemic immunotoxicity, immune cell dysfunction, cancer heterogeneity, and the immunosuppressive tumor microenvironment (ITME). Biomimetic cell-derived nanoparticles are attracting considerable interest due to their better biocompatibility and lower immunogenicity. Moreover, biomimetic cell-derived nanoparticles can achieve different preferred biological effects due to their inherent abundant source cell-relevant functions. This review summarizes the latest developments in biomimetic cell-derived nanoparticles for cancer immunotherapy, discusses the applications of each biomimetic system in cancer immunotherapy, and analyzes the challenges for clinical transformation.

• Authors: Tingting Hu, Yuezhou Huang, Jing Liu, Chao Shen, Fengbo Wu, Zhiyao He
• Journal: Pharmaceutics (Pharmaceutics) Vol. 15 Issue 7 (Jun 26 2023) ISSN: 1999-4923 [Print] Switzerland
• PMID: 37514008 (Publication Type: Journal Article, Review)